Peptides for Joint Pain and Recovery: What We Know

Patients ask me about peptides regularly now — usually BPC-157, sometimes TB-500, often in the context of recovering from an injury or trying to get a joint to settle down.

My honest answer is that there is minimal literature at this time and not enough research to draw firm conclusions from. That is not a brush-off, and it is not a judgment about anyone who has tried them. It is simply where the evidence stands, and I would rather show you that directly than give you a confident answer in either direction that the research does not support.

So this page is educational. Here is what has actually been studied, what it found, and where it stops.

The short answer

The laboratory and animal research is genuinely interesting. The human research needed to turn that into a recommendation has largely not been done.

Both of those statements are true at the same time, and most of what is written about peptides picks one and ignores the other.

What a peptide actually is

This is the most useful thing to understand, and it clears up most of the confusion on its own.

A peptide is a short chain of amino acids. That is a description of molecular structure — nothing more. It tells you nothing about whether a compound has been tested, approved, or shown to work.

Insulin is a peptide, and has been in clinical use for about a century. Semaglutide — the medication in Ozempic and Wegovy — is a peptide with large randomized trials behind it, including one in knee osteoarthritis. BPC-157 is also a peptide, and has never been through a randomized human trial for an orthopedic condition.

All three are peptides. They are not remotely comparable in terms of evidence. When an article discusses peptide therapy as though it were a single thing, that word is doing a great deal of work it cannot support.

The evidence is not one thing

It helps to think of these compounds as sitting on a range rather than in a category:

• Large randomized human trials. Insulin, semaglutide, tirzepatide. Studied in thousands of people, published in major journals, with known benefits and known side effects.
• Formal drug development in progress. Compounds currently in Phase 3 trials, where results exist but the full picture is still emerging.
• Preclinical signal, minimal human data. This is where BPC-157 sits — a substantial body of laboratory and animal research, and almost nothing in humans.
• Very little relevant research at all. TB-500 for musculoskeletal injury falls closest to here, for reasons covered below.

Nearly every meaningful question about a specific peptide comes down to which of those bands it belongs in.

BPC-157: what the research shows

BPC-157 is the one I am asked about most, and it has the largest body of research behind it of anything in this group — which is not the same as having much.

A systematic review published in 2025 in an orthopedic sports medicine journal screened more than 500 articles and included 36 studies. Thirty-five were preclinical — laboratory or animal research. One was clinical. Across animal models it improved healing of injured muscle, tendon, ligament and bone. The review classified the overall evidence at the lowest levels used in clinical research, and described human safety data as unknown.

I want to be fair to that research: improved tendon healing across multiple independent animal models is a real finding, and the proposed mechanisms are plausible rather than fanciful. What is missing is the next step — there are no randomized controlled trials in humans.

The full detail, including a distinction that matters a great deal if your question is about an arthritic joint rather than an injury, is in BPC-157 for joint pain and tendon healing.

TB-500 and thymosin beta-4

TB-500 has less behind it, and there is a distinction here that is genuinely interesting from an educational standpoint.

A scoping review published in June 2026 searched the literature through March 2026, screened 1,772 records and included 80 studies. Two findings stand out.

First, most of that research examined full-length thymosin beta-4 — a naturally occurring protein — rather than the TB-500 fragment that the term usually refers to. Those are related but not identical, and evidence about one does not automatically transfer to the other.

Second, the research that does exist has concentrated on wound and skin healing, blood vessel and endothelial tissue, the eye, and bone. Tendon, ligament, muscle, cartilage and spine — the applications people are usually asking about — were comparatively sparse.

The review found no human randomized trial supporting injection for a musculoskeletal injury, and no completed Phase 2 or Phase 3 trials of injectable TB-500 for those indications.

Why animal results do not settle it

This deserves explaining, because it is the crux of the whole subject and it is not obvious.

Most treatments that work in animals do not go on to work in people. That is not a failure of the research — it is the reason clinical trials exist.

Animal injury models are created deliberately and cleanly, usually in young healthy animals, healed over short timeframes, and measured by cutting the tissue out and testing it. A human tendon problem is typically the result of years of accumulated load in a middle-aged person with other things going on. An arthritic hip or knee is a different situation again — the cartilage is gone, not injured.

So a compound improving tendon strength in a rat at fourteen days is a reason to run a human trial. It is not a substitute for having run one.

Regulatory status

Two factual points that are worth knowing, stated plainly.

BPC-157 is not an FDA-approved medication. The FDA has included it among substances for which it has identified limited human safety information, citing questions about immunogenicity for certain routes of administration and about characterizing the compound consistently.

It is also prohibited in competitive sport under anti-doping rules. If you compete at any level with drug testing, that matters regardless of what the research eventually shows.

The regulatory picture in this area has been changing, so the status of a particular compound today may not be its status next year.

If you are having surgery

Here is the one practical request I would make.

Tell your surgeon what you are taking. Anything that may affect inflammation, healing or bleeding is relevant around an operation, and it is relevant in the same ordinary way that supplements, anti-inflammatories and blood thinners are. We ask about those for planning reasons, not to pass judgment.

Because there is no research on peptide use around joint replacement specifically, I cannot tell you it is safe and I cannot tell you it causes a problem. What I can do is take it into account if I know about it. The same principle applies to the supplements conversation and to blood thinners.

What I tell patients who ask

More or less what is on this page.

There is minimal literature at this time and not enough research for me to make a recommendation. I can go through what the studies show and where they stop, and I would rather do that than give a confident answer the evidence does not support — in either direction. I am not going to tell you it works, and I am not going to tell you it is worthless.

What I would say is this: if a joint has been hurting long enough that you are researching treatments for it, the most useful next step is usually finding out what is actually wrong with it.

If the problem is a hip or a knee

This is where I can be genuinely useful rather than only informative.

Hip and knee pain has a lot of possible causes that feel similar from the outside. Osteoarthritis, a meniscus tear, a labral tear, bursitis, referred pain from the back, and inflammatory arthritis all produce overlapping symptoms and need entirely different treatment. An examination and a weight-bearing X-ray sort out most of it in a single visit.

That matters here because the treatment that helps depends entirely on the diagnosis. There is also a great deal available for an arthritic hip or knee well short of surgery — outlined in non-surgical treatment for hip and knee arthritis — and it is worth knowing what those options are.

Knowing what you are dealing with is what makes any treatment decision a real decision rather than a guess.